Search
Urea
go.drugbank.com/drugs/DB03904ApprovedInvestigationalIt is the principal end product of protein catabolism and constitutes about one half of the total urinary solids. … A compound formed in the liver from ammonia produced by the deamination of amino acids.
Mixtures: HYDROCORTISONE 1% ET UREA 5% CREAMMipomersen
go.drugbank.com/drugs/DB05528ApprovedSpecifically, elevations in the liver enzymes, i.e. transaminases, and in liver fat (hepatic steatosis) have been reported. … Mipomersen is indicated in patients with homozygous familial hypercholesterolemia as an adjunct to diet and other lipid-lowering medications.
Categories: Compounds used in a research, industrial, or household settingChlorobutanol
go.drugbank.com/drugs/DB11386ApprovedVet approvedWithdrawnChlorobutanol, or chlorbutol, is an alcohol-based preservative with no surfactant activity [A32746]. … Similar in nature to chloral hydrate, it is formed by the simple nucleophilic addition of chloroform and acetone.
Categories: Compounds used in a research, industrial, or household settingBulevirtide
go.drugbank.com/drugs/DB15248ApprovedInvestigationalIt was first approved for use in the EU on May 28, 2020; bulevirtide has been granted PRIME scheme eligibility and Orphan Drug Designation by the European Medicines Agency. … [Peginterferon Alfa-2a]) in Patients With CHD.
Human C1-esterase inhibitor
go.drugbank.com/drugs/DB06404ApprovedInvestigational[L16586, L16606] This drug is indicated for prophylaxis and treatment of Hereditary Angioedema (HAE), a human genetic disorder caused by a shortage of C1 inhibitor activity that results in an overreaction … The disease is characterized by acute attacks of painful, and in some cases, fatal swelling of several soft tissues or edema, which may last up to five days when untreated.[L16586, L16606]
Categories: Drugs Used in Hereditary AngioedemaCilgavimab
go.drugbank.com/drugs/DB16393ApprovedInvestigationalCilgavimab, in combination with [tixagevimab], was issued an FDA emergency use authorization (EUA) on December 9, 2021, for the pre-exposure prophylaxis of COVID-19 in individuals at increased risk for … [L39411] EVUSHELD was granted marketing authorization by the EMA on March 28, 2022,[L41454] and was approved in Canada soon after, on April 14, 2022.
Tixagevimab
go.drugbank.com/drugs/DB16394ApprovedInvestigationalTixagevimab, in combination with [cilgavimab], was issued an FDA emergency use authorization (EUA) on December 9, 2021, for the pre-exposure prophylaxis of COVID-19 in individuals at increased risk for … [L39411] EVUSHELD was granted marketing authorization by the EMA on March 28, 2022,[L41454] and was approved in Canada soon after, on April 14, 2022.
Isoprenaline
go.drugbank.com/drugs/DB01064ApprovedInvestigational[L33204] Isoprenaline was granted FDA approval on 19 February 1948.[L33155] … Isoprenaline is a non-selective beta adrenergic receptor agonist indicated to treat heart block, Adams-Stokes attacks, bronchospasm in anesthesia, cadiac arrest, hypovolemic shocks, septic shock, hypoperfusion
Categories: Compounds used in a research, industrial, or household settingSynonyms: N-Isopropylnoradrenaline, N-IsopropylnorepinephrinePiflufolastat F 18
go.drugbank.com/drugs/DB14805ApprovedInvestigationalProstate cancer is the most common non-cutaneous malignancy affecting men in North America[A235344] - despite this, an ongoing challenge in prostate cancer therapy is the difficulty in imaging the extent … levels roughly 1000-fold greater than elsewhere in the body, and even higher in prostate cancer tissue.
Alclofenac
go.drugbank.com/drugs/DB13167ApprovedWithdrawnIt was withdrawn from the market in the United Kingdom in 1979.